A Minimalist Design Looks Great for Clearing Tau
Interception of Extracellular Tau by Antibodies May Be Sufficient to Stop the Spread of Tau in AD
Spherical Nucleic Acids Deliver a New Package for Oliognucleotide Therapeutics
SNAs Are a Hopeful First Step in Boosting the Utility of Oligonucleotides to Treat a Variety of Human Diseases
Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
For full access to this article login to GEN Select now.
RNAi Moves One Step Closer to Clinic
Researchers Tout Delivery Strategies that Have the Potential to Get New Drugs into Trials Sooner
- As more of the human genome is identified and characterized, new frontiers open for therapeutics. “The RNA interference (RNAi) research space continues to explode,” explains Susan Magdaleno, Ph.D., senior manager of scientists, RNAi technologies R&D, Life Technologies. “We are actually expanding into new content. Part of it is a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.